SomedebBallMD(He/Him)

PubMed

• 1 citations
  Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
  Roma A Kankaria, Jeremy B Jones, Michael Zargari, Dylan Wrinn Alexander, Hannah Angle
  Leukemia & Lymphoma. 2025-02-01
• Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
  Akriti G Jain, Virginia O Volpe, Chen Wang, Somedeb Ball, Katherine Tobon
  Annals of Hematology. 2025-01-01
• Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
  Douglas Tremblay, Clifford Csizmar, Courtney D DiNardo, Somedeb Ball, Noa Rippel
  Leukemia. 2025-01-01

Journal Articles

• Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy  
  Somedeb Ball, MD, The American Journal of Medicine

Abstracts/Posters

• Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution Experience
  Somedeb Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma
  Somedeb Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Effective Implementation of a Structured Protocol for Facilitation of the Judicious Use of Antibody Test for Diagnosis of Heparin Induced Thrombocytopenia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Thrombotic episodes in myeloproliferative neoplasms: A population based study. 
  2019 ASCO Annual Meeting - 6/1/2019
• Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all